It is noteworthy that this study tested two lower rivaroxaban doses (15 mg and 2.5 mg) as an alternative to approved drug regimen in AF patients (Rivaroxaban 20 mg when combined with P2Y12 inhibitor). The gene discussed is P2RY12; the disease is atrial fibrillation.